Media Center

Filter by:
April 08, 2024

ACC.24 Late-Breaking IMPROVE-HCM Presentation

April 08, 2024

Dr. Maron and Dr. Gibson Discuss Ninerafaxstat and IMPROVE-HCM

April 08, 2024

Journal of the American College of Cardiology

December 05, 2022

Ninerafaxstat to Provide Optimal Ventricular Energetics in HCM: IMPROVE-HCM

August 26, 2022

IMPROVE DiCE: A Phase 2a Trial Investigating Ninerafaxstat - A Novel Cardiac Mitotrope for the treatment of Diabetic Cardiomyopathy

July 05, 2021

IMB-10189721, a novel first-in-class partial fatty acid oxidation (pFOX) inhibitor improves cardiac remodelling and function post-myocardial infarction.

July 05, 2021

Phase 1 safety and tolerability study of IMB-1018972, a novel oral modulator of substrate utilization designed to improve cardiac metabolic efficiency and bioenergetics

You Are About to Leave Imbria Pharmaceuticals

The appearance of external hyperlinks does not constitute endorsement by Imbria Pharmaceuticals of the linked websites, or the information, products or services contained therein.

Back Continue